CTLA4 and melanoma: Pre-existing CD8+ TILs localized in the invasive tumor margin were predictive of melanoma response to PD-1 or CTLA-4 inhibitor therapy [57,58,59], whereas PD-L1+ melanocytes located next to TILs was shown to lead to the secretion of interferon-gamma as a form of adaptive immune resistance [60].